PainReform Ltd.

NasdaqCM PRFX

PainReform Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2023

PainReform Ltd. Return on Capital Employed (ROCE) is NA for the year ending December 31, 2023. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.
Key data
Date Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio Return on Common Equity
Market news
Loading...
NasdaqCM: PRFX

PainReform Ltd.

CEO Dr. Ehud Geller Ph.D.
IPO Date Sept. 1, 2020
Location Israel
Headquarters 65 Yigal Alon Street
Employees 7
Sector Health Care
Industries
Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Similar companies

RGC

Regencell Bioscience Holdings Limited

USD 4.86

-4.71%

FLGC

Flora Growth Corp.

USD 0.94

1.68%

PROC

Procaps Group S.A.

USD 1.76

7.98%

StockViz Staff

January 15, 2025

Any question? Send us an email